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1. Introduction
  Malaria is till now one of the burdens in the world. It is 
leading cause of sickness and death in the developing 
world. The clinical manifestations of malaria are fever, 
chills, prostration, and anemia, whereas in severe 
malarial infection, metabolic acidosis, cerebral malaria, 
multi-organ failure, coma and death may also chase. 
In the world >40% population lives with some danger of 
constricting malaria[1,2]. About 3.3 billion people-half of 
the world’s population are at risk of malaria and primarily 
among children and pregnant women. The World Health 
Organization (WHO) reports that a child dies from malaria 
every 30 s, hence about 3 000 children who are under the 
age of five die each day, summing up to over 1 million 
deaths per year. 
  In the life cycle of plasmodium parasites, sporozoites infect 
hepatocytes and proliferate into thousands of merozoites 
in the liver[3]. Merozoites rip apart from the hepatocytes, 
come in to the blood circulation and invade red blood cells 
(RBCs), where they expand first into rings and then into the 
late forms, trophozoites and schizonts. Schizont-infected 
RBCs burst and liberate more merozoites, which begin the 
blood cycle again. Because the blood stage infection is to 
blame for all symptoms and pathologies of malaria. 
  Numbers of drug have launched by FDA against the 
disease. Plasmodium infected RBCs (pRBCs) are main 
chemotherapeutic target[4]. Several drugs are evidence 
for different degrees of toxicity, which limits their use as 
recent administration forms release the free compound in 
the blood and offer slight specificity regarding the targeted 
cells[5]. Consequently, to achieve therapeutic levels that 
enlarge eventually, the first concentration of the drug in the 
body should be elevated. Alternatively, if the administered 
chemical has unspecific toxicity, the low doses essential 
contribute to the maturity of resistant parasite strains[6]. 
  To trim down the unfavorable effects arising during 
the treatment, the main entity of the modern parasitic 
chemotherapy is to object the drug particularly to the 
parasite to maximum possible coverage. Before possible 
thinking about the novel drug designing or drug delivery 
system, absolute localization of the parasite within the host 
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organ, tissue or cells should known during the acute and 
chronic phase of the disease. Moreover, following factors 
must be given due thoughtfulness[7]. 
•The relationship between the parasite and host cell
•To reach the target organ, tissue or cells, biological barrier 
system to be overcome
•Total in sequence about the receptors, present on the 
infected cells
•About the presence of antigens or receptors on the surface 
of the parasite
•Pathophysiological studies of the disease
  Recent investigations into the balanced delivery and 
targeting of pharmaceutical, curative, and analytical 
mediator are nanotechnology based drug delivery. These 
involve the recognition of accurate targets (cells and 
receptors) associated to definite clinical circumstances, and 
picking of the fitting nanocarriers to pull off the obligatory 
responses while reducing the side effects[8]. Till now various 
types of devices and strategies based on nanotechnologies 
suitable for drug delivery have been projected. In general, 
these devices may show the property of (栺) enhancement of 
drug absorption by facilitating diffusion through epithelium, 
(栻) safeguard of drug from degradation, (栿) adjustment of 
pharmacokinetics of drug and tissue distribution profiles, or/
and (桇) improvement of penetration and distribution into the 
cell[9]. 
  Due to the intracellular nature and scattered locations 
of malaria, leishmaniasis, and trypanosomiasis, parasites 
create a great challenge to scientists minded with drug 
discovery and represent a significant global burden. Most 
of the recent researches in the field of drug development 
for parasitic diseases are paying attention on the biological 
and biopharmaceutical issues to consider in the design of 
delivery strategy for illuminating these parasitic infections. 
In addition, the role of the colloidal carriers’ liposomes, 
polymeric nanoparticles, and lipid nanoparticles including 
lipid drug conjugate (LDC) nanoparticles in optimizing 
the delivery of anti-malaria, anti-leishmania and anti-
trypanosomia agents were studied[10]. In this study we found 
that age-old antimalarial drugs play more effective activity 
when it is delivered with applying the nanotechnology.
2. Current therapeutic regimen against malaria
  Malaria diseases not only cause an escalating risk to human 
health, but also remains a constant threat to the economic 
affluence of mankind. The limitation of available tools for 
the therapeutic treatment of most parasitic diseases has 
created an insecure scenario. One major limitation is drug 
resistance. Now, Artimisinine Combination Therapy (ACT) is 
frontline drug against malaria disease. 
  In particular, the artemisinins have the ability to kill a 
broad range of asexual parasite stages at safe concentrations 
that are repeatedly again achievable via standard dosing 
regimens[11]. Artemisinins have been used in traditional 
Chinese herbal medicine for more than 2 000 years but were 
not subjected to scientific inspection until the 1970s[12]. In 
the effort to minimize the risk of developing resistance, WHO 
has recommended artemisinin to use to treat uncomplicated 
malaria in combination with other antimalarials as 
artemisinin combination therapies (ACTs). With the 
deployment of ACTs in 2005/2006 have been found as first-
line treatment in several endemic countries in Africa, the 
malaria cases and deaths have been reported to be on the 
decline[13]. Artemesinin has a very different mode of action 
than conventional anti-malarials, this makes is particularly 
useful in the treatment of resistant infections, however in 
order to put a stop to the development of resistance to this 
drug it is only recommended in combination with another 
non-artemesinin based therapy (Table 1). It produces a very 
rapid reduction in the parasite biomass with an associated 
reduction in clinical symptoms and causes a lessening in the 
transmission of gametocytes thus decreasing the potential 
for the multiply of resistant alleles[14].  
  But, it is reported, parasites that have low sensitivity to 
ACTs in Combodia as well as South East Asia threaten these 
advances[15,16]. In the past, parasites that are resistant to 
CQ and anti-folate emerged from this region and spread to 
East Coast of African and from there to the rest of Africa. 
If resistance emerges against ACTs, then, the result will be 
catastrophic considering the limited number of anti-malarial 
drug currently available. Furthermore, the artemisinins are 
known for their very short half-life[16,17]. Under considering 
the conclusion above, there is an urgent need to develop 
formulations able to reduce the side effects and also to limit 
the progression of drug resistance.
3. Nanotechnology based strategy against malaria
  To overcome the challenge posed by malarial parasites as 
well as multi-drug resistant parasites, different strategies 
have taken to test for intracellular diagnosis and anti-
malarial delivery, based on nanoparticles; like functionalized 
nanoparticles, dendrimers, polymeric nanoparticles, 
liposomal nanoparticles, quantum dots, carbon nanotubes. 
Many scientist as well as researcher of different part of the 
world proposes the use of nano-medicine to address the 
current shortfalls of malaria therapies. 
3.1. Diagnosis of malaria with nanoscience
  For pure treatment of every disease, proper and precise 
diagnosis is highly essential. Although, the wide spread 
malaria treatment is started by clinical diagnostic study, 
but most of clinical signs like, headache, fever, anorexia, 
malaise, etc. are not only symptom of malaria but these 
overlap with other diseases[18]. In this connection, a case 
study shows that 1 945 children and 2 885 adult were 
suffering from fever but when their blood was kept under 
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microscope, only 7% children and 12% adult were malaria 
infected[19]. In such situations, people may be treating 
for malaria when they do not have malaria and it may 
contribute high death toll in malaria endemic zone[20,21]. So, 
it is difficult to set up the level of parasitemia by clinical 
diagnosis as a consequence of various level of tolerance by 
different patients[22]. Clinical diagnosis should therefore 
be backed by other diagnostic approaches. To avoid such 
problem, recently researchers have evaluated few diagnostic 
devices, like, dendrimer-based devices, quantum dots, 
magnetic nanoprobes, nanoshells, and nanotubes[23].
  Malaria, a disease that targets liver and red blood cells, has 
a dormant phase in the liver, which may lead to recurrence 
after several years[24]. Though the availability of antimalarial 
drugs is not an issue in endemic zone, proper diagnosis is 
the main issue. Apart from microscopic detection, lateral 
flow immune-chromatographic tests (ICT) are available 
to overcome the confines of microscopic diagnosis. The 
analysis also requires highly skilled and practiced staff, 
and detection at low-level parasitemia is often tricky. This 
technique is comparable to the microscopic diagnosis and 
is inexpensive, even though there are concerns of false 
negatives. PCR-based techniques are used for the detection 
of low-level parasitemia[25]. Various groups are working 
towards the development of an inexpensive diagnostic 
technique that will incorporate micro fluidics and genomics 
integrated with nanotechnology, in order to diagnose not 
only the type of malaria parasite but also determine drug 
resistance. 
3.2. Therapeutic application of age-old antimalarial drugs 
with nanoscience
  The main drawbacks of straight malaria chemotherapy 
is the development of multiple drug resistance and the 
wandering off the point localization to intracellular parasites, 
resulting in high dose requirements and subsequent 
intolerable side effect which eventually leads to patient non 
compliance[26]. Different strategies to deliver anti-malarial 
drugs via nano particles/carriers have been evaluated. 
Recently, the focus is placed mainly on lipid-based (e.g., 
liposomes, solid lipid nanoparticles and microemulsions) 
and polymer-based nanodrug delivery (nanocapsules and 
nanospheres)[11]. These nanocarriers are known to improve 
the efficacy of currently available anti-malarial drugs and 
contribute to the formulation and delivery of new chemical 
entities[11]. Targeting drugs specifically to their site of action 
have great advantage in malaria since malaria parasites 
frequently develop drug resistance due to the administration 
of low drug concentrations in the presence of a high parasitic 
count. Furthermore, nanomedicine has the potential to 
restore the use of old and toxic drugs by modifying their 
bio-distribution, improve bioavailability and reducing 
toxicity[11]. This advantage is particularly important in 
malaria therapy, since the development of new dosage forms 
for delivering drugs to parasite-infected cells is urgently 
needful, especially for the anti-malarial in clinical use[27]. 
Nano-carriers may also allow the use of potentially toxic 
anti-malarial, which are still under development. 
  Both passive and active nanotechnology-based drug 
delivery systems have evaluated for malaria using the 
Table 1
Briefly description of recently use artimisinin combination therapy (ACT).
Components Description
Artesunate and amodiaquine
(Coarsucam or ASAQ)
This combination has been tested and proved to be efficacious in many areas where amodiaquine retains some 
efficacy. A potential disadvantage is a suggested link with neutropenia. The WHO for uncomplicated falciparum 
malaria recommends it. Dosage is as a fixed-dose Combination (ASAQ) recommended as 4 mg/kg of Artesunate 
and 10 mg/kg of Amodiaquine per day for 3 days[15].
Artesunate and mefloquine
(Artequin or ASMQ)
This has been used as an efficacious first-line treatment regimen in areas of Thailand for many years. Mefloquine 
is known to cause vomiting in children and induces some neuropsychiatric and cardiotoxic effects, interestingly 
these adverse reactions seem to be reduced when the drug is combined with artesunate, it is suggested that this 
is due to a delayed onset of action of mefloquine. This is not considered a viable option to be introduced in Africa 
due to the long half-life of mefloquine, which potentially could exert a high selection pressure on parasites. 
It’s recommended by the WHO for uncomplicated falciparum malaria.1 The standard dose required is 4 mg/
kg per day of Artesunate plus 25 mg/kg of Mefloquine as a split dose of 15 mg/kg on day 2 and 10 mg/kg on day 
three[15].
Artemether and lumefantrine
(Coartem Riamet, Faverid,
Amatem, Lonart or AL)
This combination has been extensively tested in 16 clinical trials, proving effective in children under 5 and 
has been shown to be better tolerated than artesunate plus mefloquine combinations. There are no serious side 
effects documented but the drug is not recommended in pregnant or lactating women due to limited safety testing 
in these groups. This is the most viable option for widespread use and is available in fixed-dose formulas thus 
increasing compliance and adherence. The WHO for uncomplicated falciparum malaria recommends it[15].
Artesunate andsulfadoxine/
pyrimethamine(Ariplus or 
Amalar plus)
This is a well-tolerated combination but the overall level of efficacy still depends on the level of resistance 
to sulfadoxine and pyrimethamine thus limiting is usage. It is recommended by the WHO for uncomplicated 
falciparum malaria[12]. It is recommended in doses of 4 mg/kg of Artesunate per day for 3 days and a single dose 
of 25 mg/kg of SP[15].
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different route since they are able to deliver the drug to the 
specific target in the human body where the malaria parasite 
is located. In passive targeting, conventional nanocarriers 
(e.g. liposomes, hydrophobic polymeric nanoparticles), 
or surface-modified long-circulating nanocarriers (e.g. 
polyethylene glycol coated particles) can be used. The drug-
loaded carrier accumulates at a specific site in the body, 
especially mononuclear phagocyte system (MPS) cells, due to 
physicochemical or characteristic of the nanocarries. In passive 
targeting red blood cells (RBCs), which are not, phagocytotic 
or endocytotic cells do not act as target[11,28]. In the following 
it has been described about different nanoparticles based 
different age old anti-malarial drugs delivery and improvement 
of their efficacy in laboratory research.
3.2.1. Therapeutic approach with quinine 
  Quinine discovered from the cinchona tree, and the 
potential uses of its bark and collection of its derivatives is 
used frequently in the prevention and treatment of malaria. 
Quinine is an alkaloid (Figure 1a) and the treatment regimen 
of quinine is complex. The World Health Organization 
recommendation for quinine is 20 mg/kg first times and
10 mg/kg 8 h for 5 d where parasites are sensitive to 
quinine, combined with doxycycline, tetracycline or 
clindamycin. The recommended method depends on the 
urgency of treatment and the available resources (i.e. 
sterilized needles for IV or IM injections). Use of quinine 
is characterized by a frequently experienced syndrome 
called cinchonism. Tinnitus (a hearing impairment), rashes, 
vertigo, nausea, vomiting and abdominal pain are the most 
common symptoms. Besides it, neurological effects have 
been found in some cases due to the drug’s neurotoxin 
properties because the drug’s interactions cause a decrease 
in the excitability of the motor neuron end plates and often 
results in functional impairment of the eighth cranial nerve, 
resulting in confusion, delirium and coma. Hypoglycaemia 
is also result of quinine treatment and therefore it is advised 
that glucose levels are monitored in all patients every 4-6 
hours. During pregnancy, additional care in administering 
and monitoring the dosage is essential. Repeated or over 
dosage can result in renal failure and death through 
depression of the respiratory system.
Figure 1. Chemical structure of anti-malarial drugs.
  A report suggests that, intravenous administration of QN-
loaded nanocapsules prepared by interfacial deposition 
of poly-毰-caprolactone showed more efficacy than only 
quinine.  At 75 mg/kg/day to infected rats resulted in 100% 
survival, representing an almost 30% reduction compared 
with the free QN effective dose (105 mg/kg/day) and the 
pharmacokinetic parameters of nano-encapsulated QN 
were not significantly different from those estimated for 
free drug (alpha=0.05). The QN partition coefficient into 
infected erythrocytes doubled (6.25依0.25) when the drug 
was nano-encapsulated compared with the free drug (3.03依
0.07). Therefore, nano-encapsulation amplified the dealings 
between QN and the erythrocyte and this mechanism is 
responsible for the drug’s greater than before efficiency 
when nano-encapsulated[29]. Another study carry that, 
transferrin-conjugated solid lipid nanoparticles were 
prospective for targeted delivery of quinine di-hydrochloride 
to the brain for cerebral malaria medication[30].
3.2.2. Therapeutic approach with halofantrine 
  In 1960, the Walter Reed Army Institute of Research 
developed halofantrine. It is a phenanthrene methanol 
(Figure 1b). Its mechanism of action is similar to other 
anti-malarials. The cytotoxic complexes formed with 
ferritoporphyrin XI that cause plasmodial membrane 
damage. It was prescribed by physicians against drug 
resistant parasites infection but it is not commonly used in 
the treatment (prophylactic or therapeutic) of malaria due to 
its high cost and it has variable bioavailability and shown to 
have potentially high levels of cardio toxicity. 
  Nanotechnology has become able to reduce the bad 
effects of the free drug. The reduction of the cardiovascular 
alterations has found after injection of halofantrine 
nanocapsule (Hf-NC) in Plasmodium berghei infected mice. 
This was probably due to the ability of nanocarriers by 
modifying the distribution of the entrapped drug into the 
body. The reduction of toxic effects resulting from nano-
encasulated halofentrine treatment that could be accredited 
to a lower free fraction of the drug available for association 
with the cardiac tissue as compared with the administration 
of the drug as a solution. Few studies reveal that the free Hf 
binds extensively to lipoproteins, mainly low- and high-
density lipoproteins and results the association of the Hf 
with the oily core of nanocapsules reduces the amount of 
drug bound to lipoproteins in the blood and consequently 
lowers the fraction that would be transported to the heart 
tissue through LDL receptors. However, when halofantrine 
is  nanoencapsulated with poly-毰-caprolactone 
nanocapsules, leading to lowering the dose and increased 
solubility, significant reduction in cardiac toxicity and 
improved bioavailability was observed in comparison to 
its conventional form. It concluded that distribution and 
circulation time of drugs could be improved by these 
nanocarriers[26,31]. 
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3.2.3. Therapeutic approach with primaquine
  Primaquine, a highly active 8-aminoquinolone was use to 
treat malaria infection (Figure 1c). However, the drug was use 
in conjunction with another effective blood schizonticidal 
drug but there are few significant side effects. It has seen 
that primaquine may cause anorexia, nausea, vomiting, 
cramps, chest weakness, anaemia, some suppression of 
myeloid activity and abdominal pains. In cases of over-
dosage granulocytopenia may occur. Primaquine is one 
of the most widely used second line antimalarial acting 
specifically on the pre-erythrocytic schizonts. Ultimately, 
PQ is characterized by poor oral bioavailability and drug-
related side effects that can lead to hemolytic anaemia, 
gastrointestinal disturbances, heart failure and abdominal 
cramps[32-34]. 
  To overcome the drawbacks of PQ, a group of researcher 
incorporated the drug into an oral lipid nanoemulsion 
with particle size in the range of 10-200 nm. The efficacy 
of nanodrug have been evaluated against Plasmodium 
berghei in infected mice and was observed at 25% lower 
dosage levels than the unencapsulated form.63 Lipid nano-
emulsion of PQ exhibited improved oral bioavailability 
and was taken up preferentially by the liver with drug 
concentration higher at least by 45% as compared with the 
unencapsulated drug. It was concluded that, lipid nano-
emulsion embrace an enormous promise for delivery of PQ 
to the liver with potential to treat latent stage malaria and 
reduced toxicity[7,35]. 
3.2.4. Therapeutic approach with pyrimethamine 
  Pyrimethamine is a standard antiprotozoal drug 
recommended for prophylaxis and treatment of malarial 
infections. Limited bioavailability, slow onset of action, and 
life-threatening side effects restrict its use. Pyrimethamine 
(Figure 1d) was used for the treatment of uncomplicated 
malaria. The mode of action of the drug is to inhibit 
dihydrofolate reductase in the parasite. It prevents the 
biosynthesis of purines and pyrimidines. 
  Ionically cross-linked chitosan/tripolyphosphate 
microparticles containing pyrimethamine has formulated[36]. 
The spectral analyses confirm the occurrence of 
microencapsula t ion wi th  the  outcome of  s table 
microparticles. These microparticles should investigate 
further for clinical application as a controlled release matrix 
for the drug pyrimethamine.
  An additional study showed pyrimethamine nanosuspension 
was prepared with the objective to improve its dissolution 
rate and pharmacokinetic profile. Stable pyrimethamine 
nanosuspension with submicron particle size was prepared 
by nanoprecipitation and high-pressure homogenization 
techniques. Nanosizing and stabilizers modified the surface 
characteristics of drug particles resulting in considerable 
increase in the dissolution rate. The in vivo pharmacokinetic 
profiling of pyrimethamine nanosuspension in rats showed 
higher AUC 0-24 hand C max compared to the plain 
and marketed pyrimethamine suspensions. In contrast 
to its plain and marketed formulation, pyrimethamine 
nanosuspension showed rapid onset of action (T max 0.5 h vs. 
2 h). Thus, improved in vitro - in vivo kinetics indicated that 
nanosuspension proved to be a suitable strategy for elevating 
the therapeutic profile of pyrimethamine.
3.2.5. Therapeutic approach with chloroquine
  Chloroquine was the more effective against malaria for long 
time. Chloroquine (CQ) was one of the most useful drugs ever 
discovered[8] CQ (Figure 1e) has numerous pharmacokinetic 
and pharmacological advantages over all other anti-malarial 
drugs over eight decades of malaria therapy. Above all CQ is 
cheap, relatively safe, easy to administer and was extremely 
effective. The immense majority of widely used antimalarial 
therapies have lost their efficacy over time. It has become 
resistant to Plasmodium falciparum (P. falciparum). CQ 
also now use as first line drug against other species besides 
a report suggest that CQ is returning to combat malaria. 
Malawi, a country in Africa became to replace chloroquine 
with the combination of sulfadoxine and pyrimethamine to 
treat the malaria in the year of 1993. At that time, the clinical 
efficacy of chloroquine was less than 50%. The molecular 
marker of chloroquine-resistant P. falciparum malaria 
subsequently declined in prevalence and was undetectable 
by 2001. This is suggesting that chloroquine might once 
again be effective in Malawi[37].
For treatment of infections by the Apicomplexan parasites, 
a major goal is to reach the parasitophorous vacuoles, the 
intracellular niche for parasite growth. In this regard, lipid-
based nanocarriers and polymer- based nanovehicles have 
drawn considerable attention. Conventional, negatively 
charged chloroquine phosphate (a traditional anti-malarial) 
was prepared using dipalmitoylphosphatidylcholine and di
palmitoylphosphatidylglycerol, leading to either gel or fluid 
state liposomes, which were then tested in mice infected 
with P. berghei. An enhanced therapeutic effect observed 
in case of drug encapsulated in gel state liposomes, when 
compared to the fluid state[38].
  In this association, it  is reported that chitosan 
tripolyphosphate conjugate nanochloroquine shows their 
improved efficacy than only drug against P. berghei NK65 
infection in Swiss mice[39]. Interesting study has been shown 
by same researcher that chitosan conjugated CQ delivery 
is more potent then only CQ to attenuate the parasitemia 
and also host pathology. The study have showed that CQ in 
68.5 mg/kg body weight was less effective to attenuate the 
parasitemia and to scavenge the oxidative stress than same 
amount CQ conjugated  chitosan NPs[40]. So in future it may 
play a positive role brightly against malaria where CQ is 
treated and where CQ is resistant.
  Researchers have also explored the helpfulness of the 
polymeric nanosystems as adjuvants for old antimalarial 
drugs that  select ively  target  the pathogen.  The 
antimalarial activity of the polymeric salt, chloroquine 
salts in polyamidoamine polymers inhibits the growth of 
P. falciparum and bind preferentially to Plasmodium-
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infected red blood cells compared to uninfected cells[41]. 
3.2.6. Therapeutic approach with artemether
  Artemisinin, a chinese herb (qinghaosu) is used for the 
majority of its anti-malarial action. At present, it has 
been controlled by WHO guidelines. It have been used 
as early warning signals of impending resistance, such as 
delayed parasite clearance, low parasite reduction ratio, 
and increased gametocytemia[42]. It is also only given 
in combination with other anti-malarials. Furthermore 
artemether (AM) (Figure 1f), an inject able drug which is 
characterized by low bioavailability due to poor solubility 
and degradation in the acidic environment of the stomach 
and on the other hand injected AM is not very effective for 
rapid clearance of the parasite in severe malaria. 
  Other than, when (AM) was nano-encapsulated and 
injected, significant antimalaria activity was observed 
compared to free injected AM. This observation attributed 
to slow and sustained release of AM over a day. In active 
targeting, the surface of the nanocarriers can modify with 
cell-specific ligands (e.g., carbohydrates, proteins, peptides 
or antibodies)[43].  This will allow partisan accumulation 
of the drug in the target tissue or cell. The main goal of 
malaria therapy is to promote a high drug concentration in 
the intracellular parasitophorous vacuoles. Antimalarial 
drugs have to traverse through membranes (barriers) in 
order to access parasite targets within the infected RBC. 
The ability of a nanocarrier to stay in the blood stream for 
long time in order to perk up the interaction with infected 
RBCs and parasite membranes is important. This was 
confirmed when AM was entrapped in a long-circulating 
and site-specific system prepared with PEG-lysine type 
dendrimer and chondroitinsulfate A (CSA) for sustained and 
controlled delivery of the drug via the intravenous route of 
administration and the mean residence time increased by 
four folds compared to free AM. 
  Another report suggests that both in vitro and in vivo studies 
showed enhanced uptake of nano-capsuled drugs compared 
to free drug. Artemether, a potent and very hydrophobic 
antimalarial drug, was solubilized in dendrimers. Successful 
synthesis of dihydroartemisinin nanosuspension was done by 
dispersing ternary ground mixtures of polyvynilpyrolidone, 
sodium deoxycholate and dihydroartemisinin. Although the 
system did not yield a reduced particle size suspension, a 
more physically stable nanosuspension obtained[44].
4. Conclusions
  The application of nanotechnology to drug delivery 
has previously had a positive relevant on many areas of 
medication. With continual research and expansion efforts, 
nanotechnology is projected to have a remarkable impact 
on medicine for decades to draw closer. Pharmaceutical 
research stands for a major tactic for discovering and 
developing new drugs. Current malaria therapeutics 
commands strategies capable to selectively deliver drugs 
to Plasmodium - infected red blood cells (pRBCs) in order 
to limit the appearance of parasite resistance. Nanoparticle 
coordination to anti-malarial drugs/biologically active 
molecules can be employed as a strategy to enhance their 
activity and overcome resistance to the scientific assessment 
of nanotechnology based remedies that might be safer, 
cheaper, and less toxic than current prescription medicines. 
The expansion of efficacy of age-old drug by using 
nanovehicles is still an open area for research.
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